Wendell David Associates Inc. Reduces Stock Holdings in Stryker Co. (NYSE:SYK)

Wendell David Associates Inc. lowered its position in shares of Stryker Co. (NYSE:SYKFree Report) by 0.7% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 120,978 shares of the medical technology company’s stock after selling 880 shares during the quarter. Stryker accounts for approximately 3.9% of Wendell David Associates Inc.’s investment portfolio, making the stock its 6th biggest holding. Wendell David Associates Inc.’s holdings in Stryker were worth $36,228,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of SYK. Fairfield Bush & CO. bought a new position in shares of Stryker during the 1st quarter worth approximately $131,000. Dimensional Fund Advisors LP raised its holdings in shares of Stryker by 1.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 673,924 shares of the medical technology company’s stock worth $180,182,000 after purchasing an additional 9,026 shares during the period. Prudential PLC bought a new stake in shares of Stryker in the 1st quarter worth approximately $1,444,000. Sequoia Financial Advisors LLC raised its holdings in shares of Stryker by 21.6% in the 1st quarter. Sequoia Financial Advisors LLC now owns 3,056 shares of the medical technology company’s stock worth $817,000 after purchasing an additional 543 shares during the period. Finally, Zions Bancorporation N.A. raised its holdings in shares of Stryker by 9.2% in the 1st quarter. Zions Bancorporation N.A. now owns 3,140 shares of the medical technology company’s stock worth $839,000 after purchasing an additional 265 shares during the period. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Down 0.9 %

SYK opened at $354.67 on Tuesday. The company has a fifty day moving average price of $345.14 and a 200-day moving average price of $306.52. The firm has a market capitalization of $134.94 billion, a P/E ratio of 42.99, a price-to-earnings-growth ratio of 2.92 and a beta of 0.89. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.58 and a quick ratio of 0.97. Stryker Co. has a one year low of $249.98 and a one year high of $361.41.

Stryker (NYSE:SYKGet Free Report) last announced its earnings results on Tuesday, January 30th. The medical technology company reported $3.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.27 by $0.19. Stryker had a net margin of 15.44% and a return on equity of 22.99%. The company had revenue of $5.82 billion during the quarter, compared to analyst estimates of $5.60 billion. During the same period in the previous year, the business earned $3.00 earnings per share. The firm’s quarterly revenue was up 11.8% compared to the same quarter last year. Equities research analysts expect that Stryker Co. will post 11.86 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be given a $0.80 dividend. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $3.20 annualized dividend and a yield of 0.90%. Stryker’s dividend payout ratio (DPR) is presently 38.79%.

Insider Buying and Selling

In related news, Director Allan C. Golston sold 3,273 shares of the company’s stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $341.00, for a total value of $1,116,093.00. Following the completion of the transaction, the director now directly owns 14,242 shares in the company, valued at $4,856,522. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Stryker news, Director Allan C. Golston sold 3,273 shares of the company’s stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the completion of the sale, the director now directly owns 14,242 shares in the company, valued at $4,856,522. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Ronda E. Stryker sold 201,146 shares of the company’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $342.90, for a total transaction of $68,972,963.40. Following the sale, the director now owns 3,755,128 shares of the company’s stock, valued at $1,287,633,391.20. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 212,109 shares of company stock worth $72,845,768. Corporate insiders own 5.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on SYK. Roth Mkm lifted their price target on shares of Stryker from $345.00 to $348.00 and gave the stock a “buy” rating in a report on Wednesday, January 31st. StockNews.com raised shares of Stryker from a “hold” rating to a “buy” rating in a report on Tuesday, January 23rd. Canaccord Genuity Group raised shares of Stryker from a “hold” rating to a “buy” rating and set a $360.00 target price on the stock in a report on Wednesday, January 31st. Truist Financial boosted their target price on shares of Stryker from $330.00 to $345.00 and gave the company a “hold” rating in a report on Wednesday, January 31st. Finally, Canaccord Genuity Group raised shares of Stryker from a “hold” rating to a “buy” rating and boosted their target price for the company from $315.00 to $360.00 in a report on Wednesday, January 31st. Three research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat, Stryker presently has a consensus rating of “Moderate Buy” and an average target price of $331.52.

Get Our Latest Stock Analysis on SYK

Stryker Company Profile

(Free Report)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Featured Articles

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYKFree Report).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.